Situation: A 34-year-old woman who sells vegetables at a public market has bacteriologically confirmed, drug-susceptible pulmonary tuberculosis (TB). She starts the standard 6-month regimen under the National Tuberculosis Program (NTP) at the Rural Health Unit (RHU), with a treatment supporter from the barangay. She lives with her husband and their two children, aged 3 and 8, and takes combined oral contraceptive pills. Which advice should the nurse give her about preventing pregnancy during her TB treatment?

Rifampicin is a strong liver-enzyme inducer that lowers the level of hormonal contraceptive pills, both combined and progestin-only, so they may fail. Under the program's teaching, she should use a method not affected by this interaction, such as depot medroxyprogesterone acetate injections, a copper intrauterine device, or a barrier method. Doubling pills is unsafe and not recommended.

Core mechanism of the interaction
Rifampicin is a potent inducer of hepatic cytochrome P-450 enzymes, especially CYP3A4. It increases the metabolic clearance of estrogen and progestin components in hormonal contraceptives, lowering their serum concentrations below the threshold needed to suppress ovulation. This effect applies to both combined oral contraceptives and progestin-only pills. ^[1][2]
Because enzyme induction develops over days to weeks, contraceptive failure may not be obvious at the start of treatment, which makes anticipatory counseling essential.

Why the other options are unsafe or ineffective
Watch out! Isoniazid is not the main problem in this interaction. Although isoniazid can inhibit some CYP enzymes, the dominant clinical concern during standard TB treatment is rifampicin’s enzyme induction.
Changing to a progestin-only pill does not solve the problem because rifampicin also accelerates progestin metabolism. ^[2]
Doubling the combined pill is not recommended. It does not reliably overcome enzyme induction, increases estrogen-related side effects, and has no evidence base for TB treatment.
A copper intrauterine device or depot medroxyprogesterone acetate injection is appropriate because neither relies primarily on hepatic CYP metabolism for contraceptive efficacy. ^[1][2]

Method	Interaction with rifampicin	Recommendation during TB treatment
Combined oral contraceptive	Reduced estrogen and progestin levels due to CYP induction	Avoid or use additional barrier method
Progestin-only pill	Reduced progestin levels; same enzyme induction risk	Avoid as sole method
Doubled combined pill	Unreliable and increases adverse effects	Not recommended
Depot medroxyprogesterone acetate	Minimal reliance on hepatic CYP metabolism	Safe and effective option
Copper intrauterine device	No hormonal metabolism interaction	Safe and effective option

Clinical application in the RHU setting
A woman receiving rifampicin-based TB treatment needs contraception that remains effective despite enzyme induction. The nurse should assess her current method and offer a switch to depot medroxyprogesterone acetate, a copper intrauterine device, or consistent barrier use. The key teaching point is that rifampicin makes hormonal pills unreliable, not that the patient should take more of the same pill.
Key point! Enzyme induction persists for several weeks after rifampicin is stopped, so the interaction does not end on the last day of TB treatment. ^[1]